Tech Transfer eNews Blog

U of Arizona start-up develops advanced, low-cost treatment for sleep apnea


By Jesse Schwartz
Published: November 27th, 2019

A start-up from the University of Arizona (UA) is commercializing a technology that could revolutionize the treatment of Obstructive Sleep Apnea (OSA).

StimAire aims to replace the current, surgically implanted neural stimulation devices with a compact wearable and a tiny injectable device. By eliminating the need for surgery, the device would significantly reduce associated complications and costs.

UAVenture Capital Fund (UAVC), which supports the commercialization of UA-based technologies and services, has announced it is investing in StimAire. This marks the fund’s thirteenth investment.

According to UAVC founder and CEO Fletcher J. McCusker, the StimAire device is “one of the most important and topical inventions” ever developed at UA. “StimAire has developed a unique and innovative solution that will provide restful sleep and OSA prevention for countless apnea sufferers,” says McCusker.

The total market opportunity for StimAire’s neural stimulation is tens of billions of dollars and includes potential treatment not only of obstructive sleep apnea (OSA), but also bladder control, epilepsy, Parkinson’s and central and peripheral pain.

“As a serial entrepreneur, I’m thrilled to be part of the UAVC funding that is making a pivotal advancement in our start-up economy,” says Tarek Makansi, president and chief technology officer of StimAire.” The Tucson metro area, anchored by the University of Arizona, has what we need to carry out our ambitious plans: world-class medical professionals, sleep laboratories, clinical facilities, and top engineers and scientists.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment